(lp0
S"Insider Trading Activity Corcept Therapeutics Incorporated (NASDAQ:CORT ... Market Exclusive - 4 hours ago Patrick G. Enright , Director of Corcept Therapeutics Incorporated  reportedly Sold 269,955 shares of the company's stock at an average price of 9.94 for a total transaction amount of $2,683,352.70 SEC Form.Option Market Alert: Corcept Therapeutics Incorporated Implied Price Swing ... - CML NewsInsider Trading at Corcept Therapeutics Incorporated? - Chaffey Breeze"
p1
aS'Analyst Activity  Piper Jaffray Companies Reiterates Overweight on Corcept ... Market Exclusive - Mar 16, 2017 Today, Piper Jaffray Companies reiterated its Overweight rating on Corcept Therapeutics Incorporated  with a price target of $18.00.Corcept Therapeutics Incorporated  Soars 9.25% on March 10 - Equities.comAnalyst Recommendations And Earnings Forecast: California Resources ... - Post Analyst'
p2
aS"Corcept Therapeutics Rose 18% in March. Here's Why. Motley Fool - Apr 6, 2016 What: Shares of Corcept Therapeutics , small-cap biopharma focused on developing products for the metabolic, psychiatric, and oncologic markets, gained more than 18% in March, according to data from S&amp;P Global Market Intelligence."
p3
aS"Corcept Therapeutics: Cushing's Syndrome Is Just The Beginning Seeking Alpha - Oct 11, 2016 Shares are up over 40% since the beginning of the year, but there's plenty of upside left based on growth in the company's core business."
p4
aS'Corcept Therapeutics Incorporated  Moves Higher on Volume Spike for March 08 Equities.com - Mar 8, 2017 Corcept Therapeutics Incorporated  traded on unusually high volume on Mar. 08, as the stock gained 3.08% to close at $9.72.Corcept Therapeutics Incorporated: Corcept Therapeutics Announces Fourth ... - The Wall Street TranscriptCorcept Therapeutics Incorporated  Recent Ownership Changes - Post Analyst'
p5
aS'Insider Trading Activity Corcept Therapeutics Incorporated (NASDAQ:CORT ... Market Exclusive - Feb 28, 2017 On 12/5/2012 G Leonard Baker Jr, Director Buy, 87,131 $1.46 with an average share price of $127,211.26 View SEC Filing 11/23/2012 per share and the total transaction amounting to Daniel Bradbury.Corcept Therapeutics Incorporated  Director Sells $22025000.00 in Stock - The Cerbat GemA Look Ahead For 2 Stocks: Global Blood Therapeutics, Inc. , Corcept ... - Post Analyst'
p6
aS'Corcept Therapeutics Appoints Renee D. Gala to Board of Directors Marketwired  - Jun 28, 2016 MENLO PARK, CA-- - Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and&nbsp;...'
p7
aS'Corcept: A Profitable Biotech With A Bright Future Seeking Alpha - Jan 27, 2017 Corcept Therapeutics  is my favorite type of biotech company. It has an approved, marketed product with ramping sales, promising pipeline candidates, and is beginning to turn a profit.'
p8
aS'Corcept Therapeutics Incorporated  Moves Higher on Volume Spike for ... Equities.com - Feb 23, 2017 Corcept Therapeutics Incorporated  traded on unusually high volume on Feb. 23, as the stock gained 1.65% to close at $8.65.Stocks Roundup: EP Energy Corporation , Corcept Therapeutics ... - FactsReporterFiscal Year Earnings Estimate on Corcept Therapeutics Incorporated - Money Flow Index & Trends'
p9
aS"Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 ... Marketwired  - Jan 30, 2017 Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol,&nbsp;...Corcept Therapeutics'  CEO Joseph Belanoff on Q4 2016 Results - Earnings ... - Seeking AlphaCorcept Therapeutics Incorporated  in Traders Focus - The Newburgh Press"
p10
a.